Core Insights - Human albumin is a critical blood product widely used in emergency treatments and is considered a "lifeline" in clinical emergency and critical care in China [1] - The human albumin market in China is the largest therapeutic drug market, exceeding 30 billion yuan, with a projected growth to 57 billion yuan by 2030, reflecting a compound annual growth rate (CAGR) of 6.0% from 2025 to 2030 [1] - The partnership between Jettabell and Baiyang Pharmaceutical aims to enhance the accessibility and supply chain resilience of human albumin products in China, particularly for liver disease treatment [2][4] Market Dynamics - The human albumin market in China is characterized by high policy barriers and resource scarcity, making it a "golden track" in the biopharmaceutical sector [1] - Jettabell has a significant market share of 24% in China, with a strong focus on human albumin as a strategic product for nearly 40 years [1][3] - The demand for human albumin is expected to grow due to the aging population and increasing clinical needs [1] Strategic Collaboration - The recent agreement between Jettabell and Baiyang Pharmaceutical grants Baiyang exclusive rights to promote and distribute Jettabell's human albumin product, Ambomai®, in specific markets in mainland China [4] - This collaboration is expected to leverage Baiyang's established commercialization capabilities and market network to better serve the growing demand for high-quality blood products in China [4][5] - Both companies aim to enhance the quality and accessibility of human albumin treatments, contributing to the broader goal of improving patient health and quality of life in China [5]
百洋医药携手杰特贝林 深度布局中国血液制品黄金赛道